SRR1313117
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.510
- ESTROGEN_RESPONSE_LATE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.300
- FATTY_ACID_METABOLISM+0.290
- PROTEIN_SECRETION+0.290
- ADIPOGENESIS+0.260
- BILE_ACID_METABOLISM+0.260
- ANDROGEN_RESPONSE+0.210
- PEROXISOME+0.170
- HEME_METABOLISM+0.140
Top 10 suppressed
- E2F_TARGETS-0.580
- ALLOGRAFT_REJECTION-0.550
- INTERFERON_GAMMA_RESPONSE-0.520
- G2M_CHECKPOINT-0.490
- INTERFERON_ALPHA_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- COMPLEMENT-0.380
- MITOTIC_SPINDLE-0.360
- MYC_TARGETS_V2-0.360
- HEDGEHOG_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518189 | — | F | 0.836 |
| 2 | SRR8518242 | — | F | 0.834 |
| 3 | SRR8613744 | — | F | 0.828 |
| 4 | C3L-01889 | — | cohortA2 | 0.826 |
| 5 | SRR29022834 | — | A | 0.820 |
| 6 | AUR-AFUP-TTM1-A-1-1-R-A743-41 | — | B | 0.819 |
| 7 | SRR3147736 | — | — | 0.815 |
| 8 | 20070142.Her2HRpos | — | B | 0.811 |
| 9 | 20070161.TNBC | — | F | 0.803 |
| 10 | SRR1313112 | — | B | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.510 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |